Genital Herpes (GH), is a common sexually transmitted disease caused due to two viruses namely: herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) characterized by lifelong infection and periodic reactivation with no cure. Viruses penetrate the body through mucous membranes which line the openings of nose, mouth and genitalia.HSV1, HSV2 are found in body fluids of infected person.
The appearance of a blister is known as outbreak. First outbreak will appear as early as two days after the virus has been contracted, or as late as 30 days afterward. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving.
Symptoms of primary infection may include malaise, fever, or localized lymphadenopathy. Subsequent outbreaks, caused by reactivation of latent virus, are usually milder. Although HSV-1 and HSV-2 cannot be istinguished visually, they exhibit differences in behavior that may affect management. Patients with HSV-2 have a higher risk of acquiring human immunodeficiency virus (HIV) infection.
The Genital Herpes market report provides current treatment practices, emerging drugs, Genital Herpes market share of the individual therapies, current and forecasted Genital Herpes market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Genital Herpes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key highlights of Genital Herpes Market
According to DelveInsight, the total prevalent population of Genital Herpes in 7 major markets was 82,662,204 in 2017 and is expected to grow for the study period [2017–2030].
As per Delveinsight, the United States had registered 41,589,239 prevalent cases of Genital Herpes in 2017.
Among the European countries, Germany has the highest prevalent population of Genital Herpes with 7,008,717 cases and the United Kingdom has the lowest number of cases.
Request for sample pages:
The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders..
According to Delveinsight, the United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan.
Among the EU5 countries, Germany has the highest market size, while the UK has the lowest market size of Genital Herpes in 2017.
The Genital Herpes epidemiology division provides insights about historical and current Genital Herpes patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Genital Herpes epidemiology part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
According to the Delveinsight, Genital Herpes is more prevalent among the females as compared to the males
Drug chapter segment of the Genital Herpes report encloses the detailed analysis of Genital Herpes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps to understand the Genital Herpes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently three FDA approved antiviral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States.
The dynamics of Genital Herpes market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies and most awaited vaccines during the forecasted period of 2019–2030. Some of the key companies in Genital Herpes Market includes:
Table of Content
1. Key Insights
2. Executive Summary of Genital Herpes
3. Competitive Intelligence Analysis for Genital Herpes
4. Genital Herpes: Market Overview at a Glance
5. Genital Herpes: Disease Background and Overview
6. Genital Herpes Market Patient Journey
7. Genital Herpes Epidemiology and Patient Population
8. Genital Herpes Market Treatment Algorithm, Current Treatment, and Medical Practices
9. Genital Herpes Market Unmet Needs
10. Key Endpoints of Genital Herpes Treatment
11. Genital Herpes Market Marketed Products
12. Genital Herpes Market Emerging Therapies
13. Genital Herpes Seven Major Market Analysis
14. Attribute analysis
15. Genital Herpes Market Outlook
16. Access and Reimbursement Overview of Genital Herpes
17. KOL Views on Genital Herpes Market
18. Genital Herpes Market Market Drivers
19. Genital Herpes Market Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States